FiercePharmaOriginal article
{"a":[{"_":"BioMarin pads case for Voxzogo expansion as achondroplasia competition field shifts","$":{"href":"/pharma/biomarin-pads-case-voxzogo-expansion-achondroplasia-competition-field-shifts","hreflang":"en"}}]}
Phase 3positiveVoxzogoPositive
AI Analysis
Summary
BioMarin achieved a phase 3 win for Voxzogo in achondroplasia and recently submitted an FDA filing, advancing expansion plans for the dwarfism drug amid increased competition in the indication.
Clinical Trial Data
Phase
3
Primary Endpoint
Met
Outcome Details
Phase 3 win for Voxzogo in achondroplasia
Importance:7/10
Sentiment:
0.60
Phase 3 dataFDA filingVoxzogoachondroplasiaexpansiondwarfism
Related Companies
Read the original article
Published by FiercePharma on September 9, 2026 10:36 AM